ARTICLE | Company News
Eisai, U.S. Department of Defense infectious, antibodies news
November 1, 2010 7:00 AM UTC
The DoD awarded Eisai's Morphotek Inc. subsidiary $2.5 million to further develop preclinical mAb therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains. In 2008, Morph...